ETV6
- Known as:
- ETV6
- Catalog number:
- P100807_P050
- Product Quantity:
- 50 µg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- ETV6
Related genes to: ETV6
- Gene:
- ETV6 NIH gene
- Name:
- ETS variant 6
- Previous symbol:
- -
- Synonyms:
- TEL
- Chromosome:
- 12p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-11-28
- Date modifiied:
- 2019-04-23
Related products to: ETV6
anti-ETV6 Telanti-ETV6 Tel type: Primary antibodies host: Mouseanti-ETV6 / Telanti-ETV6 / Tel (3B10)Anti-Human ETV6, Rabbit PolyclonalBos taurus,Bovine,ETV6,Transcription factor ETV6Bovine ets variant 6 (ETV6) ELISA kit, Species Bovine, Sample Type serum, plasmaBovine Transcription factor ETV6(ETV6) ELISA kitBovine Transcription factor ETV6(ETV6) ELISA kit SpeciesBovineELISA Kit FOR Transcription factor ETV6; organism: Mouse; gene name: Etv6ETS translocation variant 6,ETS-related protein Tel1,ETV6,Homo sapiens,Human,Tel,TEL,TEL1,Transcription factor ETV6ETS translocation variant 6,ETS-related protein Tel1,Etv6,Mouse,Mus musculus,Tel,Tel,Tel1,Transcription factor ETV6ETV4 Gene ets variant 4ETV6 TEL1 antibody Ab host: RabbitETV6 TEL1 antibody Ab host: Rabbit Related articles to: ETV6
- Three-dimensional genome organization shapes gene regulation during normal B-cell development, and its disruption contributes to the initiation and progression of B-cell acute lymphoblastic leukemia. Through multi-omic studies, Ghebrechristos and colleagues revealed that transcription factors, including ERG in ETV6::RUNX1 leukemia, remodel chromatin interactions to sustain oncogenic gene expression programs, identifying genome architecture as both a driver of leukemogenesis and a potential therapeutic vulnerability. See related article by Ghebrechristos et al., p. XX . - Source: PubMed
Publication date: 2026/05/18
Gruber Tanja A - Secretory breast carcinoma (SBC) is an extremely rare subtype, accounting for ~1% of breast cancers but representing the most common malignant breast tumor in pediatric patients. Although generally indolent, SBC carries a risk of local recurrence even decades after treatment. Its defining molecular hallmark is the ETV6-NTRK3 fusion. - Source: PubMed
Publication date: 2026/05/14
Vlahović ANikolić SDjuričić S MDunđerović DIlić NSarajlija ADenčić Fekete MCvetinović AVasić M - Acute myocardial infarction (AMI) involves complex immune responses and cellular interaction mechanisms. Although the pathogenesis of AMI is now preliminarily understood, there is still a lack of biomarkers that can accurately and rapidly diagnose its disease characteristics. - Source: PubMed
Publication date: 2026/05/13
Liu ZhenfangSong JiaLi LinglingFan ZiyinXie GenyuanYang Li - gene fusions are oncogenic drivers for a variety of adult and pediatric tumors, making them a target for tumor-agnostic precision medicine. Tropomyosin receptor kinase (TRK) inhibitors are approved by the US Food and Drug Administration for cancers driven by TRK fusions. However, genes can fuse with many different partner genes, leading to diverse TRK fusion proteins, highlighting the importance of identifying the specific fusion partner with optimal pan-cancer diagnostics. This analysis aims to provide an updated descriptive compendium of gene fusions. - Source: PubMed
Publication date: 2026/05/06
Yang Soo-RyumRepetto MatteoRudzinski Erin RLi Marilyn MRoy AngshumoyGutstein LaurenHuang KarenWu JinhuaGlade Bender JuliaBrega NicolettaBuchberg Arthur MBernard-Gauthier VadimHong David SDrilon AlexanderLaetsch Theodore W - Epithelioid fibrous histiocytoma (EFH) is a benign cutaneous neoplasm that is now recognized to be largely driven by rearrangements. Rare cases of EFH and EFH-spectrum tumors with other receptor tyrosine kinase (RTK) fusions including and have been described, demonstrating the molecular heterogeneity of this entity. Herein, we report a 9-year-old female with a 1.5 cm right lateral chest wall lesion showing classic EFH morphology. Histology demonstrated a nodular dermal tumor extending to dermo-epidermal junction above and subcutaneous tissue below. The lesion was characterized by sheets of bland epithelioid/histiocytoid cells with a vaguely whorled architecture, prominent vessels, focal myxoid stroma, and no significant atypia, mitoses, or necrosis. On immunohistochemistry, the lesional cells were highlighted by CD68 and CD163, with patchy CD99 positivity. The lesional cells were negative for AE1/AE3, CD34, SMA, Desmin, S100, SOX10, CD10, ERG, CD1a, Langerin, CD30, and CD31. INI-1 was retained. Targeted solid tumor fusion analysis showed an fusion. This case expands the molecular spectrum of EFH beyond rearrangements and previously described and fusions. - Source: PubMed
Publication date: 2026/05/05
Challa BinduNaous RanaKirschner RichardReshmi Shalini CPrasad Vinay